ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • December 28th, 2018 • Tcr2 Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledDecember 28th, 2018 Company Industry JurisdictionThis Royalty Transfer Agreement (the “Agreement”) is made and entered into on May 26, 2016 (the “Effective Date”), by and between TCR2, Inc., a Delaware corporation (the “Company”), MPM Oncology Charitable Foundation, Inc. a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation “Optimus.” and together with the MPM Charitable Foundation, the “Charitable Foundations”).
ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • September 11th, 2020 • Oncorus, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledSeptember 11th, 2020 Company Industry JurisdictionThis Royalty Transfer Agreement (the “Agreement”) is made and entered into as of March 31, 2016 (the “Effective Date”), by and between Oncorus, Inc., a Delaware corporation (the “Company”), MPM Oncology Charitable Foundation, Inc., a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, the “Charitable Foundations”).
AMENDED AND RESTATED ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • February 26th, 2021 • Werewolf Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledFebruary 26th, 2021 Company Industry JurisdictionThis Amended and Restated Royalty Transfer Agreement (the “Agreement”) is made and entered into on August 2, 2019 (the “Effective Date”), by and between Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), MPM Oncology Impact Fund Charitable Foundation, Inc., a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, the “Charitable Foundations”).
AMENDMENT NUMBER 1 TO ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • March 9th, 2023 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 9th, 2023 Company Industry JurisdictionThis Amendment Number 1 to Royalty Transfer Agreement (this “Amendment”), dated as of June 6, 2022, is made by and among Cullinan Pearl Corp., a Delaware corporation (the “Company”), MPM Oncology Charitable Foundation, Inc., a Massachusetts charitable foundation (“MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, each a ”Charitable Foundation” and together, the “Charitable Foundations”) and amends that certain Royalty Transfer Agreement, dated as of October 25, 2019, by and among the Company and the Charitable Foundations (the “Royalty Transfer Agreement”). All capitalized terms used herein that are not otherwise defined herein shall have their respective meanings as set forth in the Royalty Transfer Agreement.
ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • December 27th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledDecember 27th, 2018 Company Industry JurisdictionThis Royalty Transfer Agreement (the “Agreement”) is made and entered into on December 1, 2016 (the “Effective Date”), by and between Harpoon Inc., a Delaware corporation (the “Company”), MPM Oncology Charitable Foundation, Inc., a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, the “Charitable Foundations”).
ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • December 18th, 2020 • Cullinan Oncology, LLC • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledDecember 18th, 2020 Company Industry JurisdictionThis Royalty Transfer Agreement (the “Agreement”) is made and entered into on [date] (the “Effective Date”), by and between [Cullinan Asset Subsidiary], a Delaware corporation (the “Company”), MPM Oncology Charitable Foundation, Inc., a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, each a “Charitable Foundation” and together the “Charitable Foundations”).